WHO Says Seeks More Data From Merck on COVID-19 Anti-Viral, From Bharat on Vaccine

11 months ago 116

An experimental COVID-19 attraction    pill called molnupiravir being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP, is seen successful  this undated photograph  obtained by Reuters connected  May 17, 2021. (Merck & Co. Inc./Handout via Reuters)

An experimental COVID-19 attraction pill called molnupiravir being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP, is seen successful this undated photograph obtained by Reuters connected May 17, 2021. (Merck & Co. Inc./Handout via Reuters)

GENEVA—The World Health Organization (WHO) said connected Thursday that it was seeking further data from Merck connected its experimental caller antiviral COVID-19 pill and hoped to contented guidance successful coming weeks regarding its usage for mild and mean cases.

“This is simply a cause that we are presently evaluating and we met with Merck connected Friday to sermon information from their existent objective trials that are nether mode successful different countries,” WHO adept Maria van Kerkhove told a quality league wherever she was asked astir Merck’s molnupiravir, developed with Ridgeback Biotherapeutics.

“So we anticipation to person immoderate bully quality determination successful the coming weeks.”

Mariangela Simao, WHO assistant-director, said that WHO hoped to scope a determination connected imaginable exigency usage listing for Bharat Biotech’s Covaxin vaccine astatine a Nov. 3 gathering aft asking the Indian institution this week for much objective data.

Reuters

Follow

More articles from this author

EPOCH TV